Cetuximab retargeting of adenovirus via the epidermal growth factor receptor for treatment of intraperitoneal ovarian cancer. ανά Morrison, J, Briggs, S, Green, N, Thoma, C, Fisher, K, Kehoe, S, Seymour, L

The effect of polymer coating and different adenovirus serotypes on the innate immune responses to intraperitoneal adenovirus ανά Thoma, C, Seaton, P, Briggs, S, Fisher, K, Greaves, D, Seymour, L, Morrison, J

Epidermal growth factor receptor blockers for the treatment of ovarian cancer ανά Morrison, J, Thoma, C, Goodall, R, Lyons, T, Gaitskell, K, Wiggans, A, Bryant, A

Optimally stealthed Adenovirus serotype 5 shows enhanced activity and resistance to neutralisation ανά Thoma, C, Subr, V, Illingworth, S, Morrison, J, Fisher, K, Ulbrich, K, Seymour, L, Carlisle, R

Adenovirus serotype 11 causes less long-term intraperitoneal inflammation than serotype 5: implications for ovarian cancer therapy. ανά Thoma, C, Bachy, V, Seaton, P, Green, N, Greaves, D, Klavinskis, L, Seymour, L, Morrison, J

Combining virotherapy and angiotherapy for the treatment of breast cancer. ανά Bazan-Peregrino, M, Sainson, R, Carlisle, R, Thoma, C, Waters, R, Arvanitis, C, Harris, A, Hernandez-Alcoceba, R, Seymour, L

Combining virotherapy and angiotherapy for the treatment of breast cancer ανά Bazan-Peregrino, M, Sainson, R, Carlisle, R, Thoma, C, Waters, R, Arvanitis, C, Harris, A, Hernandez-Alcoceba, R, Seymour, L